Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/67265
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro |
Author: | Cantley, M. Fairlie, D. Bartold, P. Rainsford, K. Le, G. Lucke, A. Holding, C. Haynes, D. |
Citation: | Journal of Cellular Physiology, 2011; 226(12):3233-3241 |
Publisher: | Wiley-Liss |
Issue Date: | 2011 |
ISSN: | 0021-9541 1097-4652 |
Statement of Responsibility: | M. D. Cantley, D. P. Fairlie, P. M. Bartold, K. D. Rainsford, G. T. Le, A. J. Lucke, C. A. Holding and D. R. Haynes |
Abstract: | Histone deacetylase inhibitors (HDACi) suppress cancer cell growth, inflammation, and bone resorption. The aim of this study was to determine the effect of inhibitors of different HDAC classes on human osteoclast activity in vitro. Human osteoclasts generated from blood mononuclear cells stimulated with receptor activator of nuclear factor kappa B (RANK) ligand were treated with a novel compound targeting classes I and II HDACs (1179.4b), MS-275 (targets class I HDACs), 2664.12 (targets class II HDACs), or suberoylanilide hydroxamic acid (SAHA; targets classes I and II HDACs). Osteoclast differentiation was assessed by expression of tartrate resistant acid phosphatase and resorption of dentine. Expression of mRNA encoding for osteoclast genes including RANK, calcitonin receptor (CTR), c-Fos, tumur necrosis factor (TNF) receptor associated factor (TRAF)6, nuclear factor of activated T cells (NFATc1), interferon-β, TNF-like weak inducer of apoptosis (TWEAK), and osteoclast-associated receptor (OSCAR) were assessed. Expression of HDACs 1–10 during osteoclast development was also assessed. 1179.4b significantly reduced osteoclast activity (IC50 < 0.16 nM). MS-275 (IC50 54.4 nM) and 2664.12 (IC50 > 100 nM) were markedly less effective. A combination of MS-275 and 2664.12 inhibited osteoclast activity similar to 1179.4b (IC50 0.35 nM). SAHA was shown to suppress osteoclast activity (IC50 12 nM). 1179.4b significantly (P < 0.05) reduced NFATc1, CTR, and OSCAR expression during the later stages of osteoclast development. Class I HDAC 8 and Class II HDAC5 were both elevated (P < 0.05) during osteoclast development. Results suggest that inhibition of both classes I and II HDACs may be required to suppress human osteoclastic bone resorption in vitro. |
Keywords: | Cells, Cultured Osteoclasts Dentin Humans Bone Resorption Benzamides Hydroxamic Acids Pyridines Histone Deacetylases Acid Phosphatase Isoenzymes Tumor Necrosis Factors TNF Receptor-Associated Factor 6 Proto-Oncogene Proteins c-fos Interferon-beta Receptors, Cell Surface Receptors, Calcitonin RNA, Messenger Cell Differentiation Gene Expression Regulation Dose-Response Relationship, Drug Time Factors NFATC Transcription Factors RANK Ligand Receptor Activator of Nuclear Factor-kappa B Histone Deacetylase Inhibitors Tartrate-Resistant Acid Phosphatase Cytokine TWEAK Vorinostat |
Rights: | Copyright © 2011 Wiley Periodicals, Inc. |
DOI: | 10.1002/jcp.22684 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/453568 http://purl.org/au-research/grants/nhmrc/569735 |
Published version: | http://dx.doi.org/10.1002/jcp.22684 |
Appears in Collections: | Aurora harvest Medical Sciences publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.